RxDoctor Payments Data

Kimberly Harbin, MD

Family Medicine · Cairo, GANPI 1790731867

Payments from drug & device makers

$5,146in general payments, 2019–2025

Across 196 payments — averaging $26.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$1K
  • AstraZeneca$719
  • AbbVie$588
  • Amgen$493
  • Bayer$467
  • Lilly USA, LLC$368
  • plus $1K from 16 others

What the payments were for

  • Food & beverage$5,146100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,146 in reported general payments places this provider in the 85th percentile of 3,111 family medicine providers in Georgia.

See all family medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$123,056
Medicare patients
286
Services billed
2,618

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol241$231,755
JardianceEmpagliflozin149$135,270
OzempicSemaglutide112$109,157
MounjaroTirzepatide69$80,265
KerendiaFinerenone50$66,983
LinzessLinaclotide44$43,139
TrulicityDulaglutide32$42,579
EliquisApixaban45$37,396
Trelegy ElliptaFluticasone/Umeclidin/Vilanter42$37,380
XareltoRivaroxaban40$31,211
EntrestoSacubitril/Valsartan17$24,485
Breztri AerosphereBudesonide/Glycopyr/Formoterol15$11,259
PremarinEstrogens, Conjugated15$5,236
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl34$3,768
Atorvastatin Calcium457$3,664

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Breztri Aerosphere$719$243,014256 claims
Boehringer IngelheimJardiance$107$135,270149 claims
Lilly USA, LLCMounjaro, Trulicity$368$122,844101 claims
Novo NordiskOzempic$1,058$109,157112 claims
BayerKerendia$467$66,98350 claims
AbbVieLinzess$588$43,13944 claims
PfizerEliquis, Premarin$31$42,63360 claims
GSKTrelegy Ellipta$350$37,38042 claims
Johnson & JohnsonXarelto$314$31,21140 claims
NovartisEntresto$41$24,48517 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,111 family medicine providers in Georgia.

Other family medicine in Cairo

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →